https://www.selleckchem.com/pr....oducts/bay-61-3606.h
Patients with MF/SS who require systemic therapy often progress through multiple agents sequentially, thus the need for additional novel agents in the treatment armamentarium. Antibody based therapies such as alemtuzumab are highly effective in the blood compartment of disease, while brentuximab vedotin has shown higher activity in skin and nodes. Checkpoint inhibitors may play a role in MF/SS but may induce hyper progression, and engineered T cells and bispecific antibodies recruiting immune effectors are being developed and may sh
Like
Comment
Share
